Patents Assigned to Riboscience LLC
  • Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
    Patent number: 12029744
    Abstract: The present disclosure provides certain bicyclic heteroaryl compounds that inhibit ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) enzymatic activity and are therefore useful for the treatment of diseases and conditions modulated at least in part by ENPP1. In some embodiments, the bicyclic heteroaryl compounds includes those of Formula (I). Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: July 9, 2024
    Assignee: Riboscience LLC
    Inventors: Ronald Hawley, Klaus Klumpp
  • 4?-fluoro-2?-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
    Patent number: 10953030
    Abstract: Cytidine nucleoside analogues of Formula I, wherein the variables are as described herein, in combination with uridine nucleoside analogues of Formula II, wherein the variables are as described herein, produce a synergistic effect on the inhibition of HCV polymerase.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: March 23, 2021
    Assignee: Riboscience LLC
    Inventors: Mark Smith, Klaus G. Klumpp
  • 4?-fluoro-2?-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
    Patent number: 10682369
    Abstract: Cytidine nucleoside analogues of Formula I, wherein the variables are as described herein, in combination with uridine nucleoside analogues of Formula II, wherein the variables are as described herein, produce a synergistic effect on the inhibition of HCV polymerase.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: June 16, 2020
    Assignee: Riboscience LLC
    Inventors: Mark Smith, Klaus G. Klumpp
  • 4?-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza RNA replication
    Patent number: 10092649
    Abstract: The application discloses nucleoside derivatives of Formula I as inhibitors of Influenza RNA replication. In particular, the application discloses the use of purine and pyrimidine nucleoside derivatives of Formula I as inhibitors of Influenza RNA replication and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: October 9, 2018
    Assignee: Riboscience LLC
    Inventors: Mark Smith, Klaus G. Klumpp
  • 4?-fluoro-2?-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
    Patent number: 9895442
    Abstract: The present disclosure relates to the compound of Formula I: Also disclosed are pharmaceutical compositions comprising the compound of Formula I, methods of using the compound of Formula I and/or compositions comprising the compound of Formula I for the treatment of HCV.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: February 20, 2018
    Assignee: Riboscience LLC
    Inventors: Mark Smith, Klaus G. Klumpp
  • 4?-azido, 3?-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication
    Patent number: 9708357
    Abstract: The present invention relates to the use of 3?-fluoro, 4?-azido nucleoside phosphoramidate prodrug derivatives of formula I wherein the symbols are as defined in the specification, to pharmaceutically acceptable salts thereof, and to pharmaceutical compositions containing such compounds for the treatment of HCV.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: July 18, 2017
    Assignee: Riboscience, LLC
    Inventors: Mark Smith, Francisco Xavier Talamas, Jing Zhang, Zhuming Zhang
  • 4?-azido, 3?-deoxy-3?-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication
    Patent number: 9694028
    Abstract: The present disclosure relates to the compound of Formula I: Also disclosed are pharmaceutical compositions comprising the compound of Formula I, methods of using the compound of Formula I and/or compositions comprising the compound of Formula I for the treatment of HCV.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: July 4, 2017
    Assignee: Riboscience LLC
    Inventors: Mark Smith, Klaus G. Klumpp
  • 4?-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza RNA replication
    Patent number: 9370569
    Abstract: The application discloses nucleoside derivatives of Formula I as inhibitors of Influenza RNA replication. In particular, the application discloses the use of purine and pyrimidine nucleoside derivatives of Formula I as inhibitors of Influenza RNA replication and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: June 21, 2016
    Assignee: Riboscience LLC
    Inventors: Mark Smith, Klaus G. Klumpp
  • 4?-azido, 3?-deoxy-3?-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication
    Patent number: 9249176
    Abstract: The present disclosure relates to the compound of Formula I: Also disclosed are pharmaceutical compositions comprising the compound of Formula I, methods of using the compound of Formula I and/or compositions comprising the compound of Formula I for the treatment of HCV.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: February 2, 2016
    Assignee: Riboscience LLC
    Inventors: Mark Smith, Klaus G. Klumpp
  • 2?, 4?-difluoro-2?-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
    Patent number: 9108999
    Abstract: The present disclosure relates to compounds of Formula (I): Also disclosed are pharmaceutical compositions comprising compounds of Formula (I), methods of using the compounds of Formula (I) and/or compositions comprising the compounds of Formula (I) for the treatment of HCV.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: August 18, 2015
    Assignee: Riboscience LLC
    Inventors: Jing Zhang, Zhuming Zhang
  • 4'-FLUORO-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION
    Publication number: 20140341847
    Abstract: The present disclosure relates to the compound of Formula I: Also disclosed are pharmaceutical compositions comprising the compound of Formula I, methods of using the compound of Formula I and/or compositions comprising the compound of Formula I for the treatment of HCV.
    Type: Application
    Filed: May 15, 2014
    Publication date: November 20, 2014
    Applicant: Riboscience LLC
    Inventors: Mark Smith, Klaus G. Klumpp